The term the Office gave you can be the term that kills the claim

How to read the ledger below. Each numbered point carries the kind of evidence behind it. ESTABLISHED is stated in the authority's own text, with a locator. IMPLEMENTED is the rule as the authority actually applied it. OBSERVED is carried by a source outside this one. ASSUMED is the drafter's inference, flagged as such and not the authority speaking. Quotations are checked against a cached copy of the primary source by script.

In one paragraph

The Federal Circuit affirmed the Patent Trial and Appeal Board in In re Cellect on 28 August 2023 and held that patent term adjustment is added before an obviousness-type double patenting comparison while patent term extension is added after it, so four related Cellect patents lost their asserted claims to the one family member that received no adjustment and expired 20 years from the priority filing. The court also held that good faith does not preserve the extra term and that a terminal disclaimer cannot be filed once a patent has expired.

Reader summary

Cellect owned four interrelated patents, all claiming priority from one application, all continuations-in-part within a single family. Each received patent term adjustment for Office delay. One family member, the '036 patent, received none, so it expired exactly twenty years from the priority filing. In reexaminations requested by an infringement defendant, every challenged claim was found unpatentable for obviousness-type double patenting, and every invalidation traced back through the family to that one adjustment-free patent.

The legal question was narrow and consequential: when you compare expiration dates to decide which patent is the later-expiring one, do you use the date before adjustment or after? Cellect argued for before, leaning on Novartis v. Ezra, where the court had refused to let a judge-made doctrine cut off a statutory term extension.

The court held the opposite for adjustment, and drew a hard line between the two mechanisms. Extension under Section 156 is added after the double-patenting analysis; adjustment under Section 154 is added before it. The difference is statutory: Section 154 expressly subordinates adjustment to a filed terminal disclaimer and Section 156 says nothing of the kind, so treating them alike would be "an unjustified attempt to force disparate statutes into one."

Two further holdings matter more to daily practice than the headline. Good faith is irrelevant: showing you did not manipulate prosecution does not save the term. And the cure expired with the patents. A terminal disclaimer "is not an escape hatch to be deployed after a patent expires," and invalidating only the adjustment period would have been a retroactive disclaimer the court refused to grant.

Why this matters when you are drafting

Adjustment on a continuation is a liability whenever an earlier-expiring relative exists. The instinct that extra term is a windfall is exactly what failed here. In a family sharing one priority date, the member with the least adjustment sets the effective ceiling, and any relative whose claims are obvious over it is exposed above that ceiling. When you are deciding what to claim in a new branch, the relevant question is not whether the branch is patentably distinct from the parent in the abstract, but whether it is distinct from the earliest-expiring member of the family.

File the disclaimer while everything is alive. Claim 13 is the operative deadline, and it is unforgiving: the cure vanishes at expiration, and the court will not grant a retroactive equivalent. The opinion also notes disclaimers can be filed during prosecution even with no rejection outstanding, which makes this a drafting-time decision rather than a response-to-rejection decision.

There is no partial cure. Claim 14 forecloses the intuitive compromise of surrendering only the adjusted tail. The claim falls entirely.

Do not build a defense on conduct. Claims 11 and 12 dispose of good faith, absence of gamesmanship, and promises about future ownership. The analysis is structural. Advice that rests on how a client has behaved, or intends to behave, is advice this case says will not hold.

Know what the case does not decide. Claim 15 is the most under-quoted part of the opinion. Non-asserted claims keep their full adjusted term unless separately found to be later-filed obvious variants. A summary that says "Cellect invalidated the patents" is wrong about the unit of analysis.

Keep the extension line straight. Claims 3, 4 and 7 mark the boundary the court drew between the two mechanisms. Novartis v. Ezra, which gets its own record in this corpus, is what governs extension, and Cellect expressly does not disturb it.

What the authority establishes

1. [ESTABLISHED, the disposition] The Board was affirmed in full: "the decision of the Board is affirmed." (P. 25.)

1. [ESTABLISHED, the family structure that produced the result] The four challenged patents all claim priority from one application, and all invalidations trace to the one member with no adjustment: "all invalidated claims can be traced back to the single family member patent that did not receive a grant of PTA". (P. 5.) That patent, the '036, expired October 6, 2017, twenty years from the priority filing. (P. 22.)

1. [ESTABLISHED, the core holding] "we agree with the USPTO that PTA and PTE should be treated differently from each other when determining whether or not claims are unpatentable under ODP". (P. 15.)

1. [ESTABLISHED, the rule stated as a pair] For extension, the analysis uses "the expiration date used for an ODP analysis where a patent has received PTE is the expiration date before the PTE has been added" (P. 15.); for adjustment, "PTA is the expiration date after the PTA has been added". (P. 16.)

1. [ESTABLISHED, the holding restated for the disclaimer-free case] Double patenting for an adjusted patent, "regardless whether or not a terminal disclaimer is required or has been filed, must be based on the expiration date of the patent after PTA has been added". (P. 21.) The qualifier matters: no disclaimer had been filed here, so the rule is not limited to patents already carrying one.

1. [ESTABLISHED, why the two statutes differ] Collapsing them would be "an unjustified attempt to force disparate statutes into one". (P. 16.) Each of the two mechanisms, the court says, "has its own independent framework established through an independent statutory schema". (P. 18.)

1. [ESTABLISHED, the purposive distinction] "PTE is designed to effectively extend the overall patent term for a single invention due to regulatory delays in product approval" while "PTA is designed to extend the term of a particular patent due to delays in the processing of that patent". (P. 18.)

1. [IMPLEMENTED] The court's textual hook is that Section 154(b)(2)(B) subordinates adjustment to a filed terminal disclaimer and Section 156 contains no equivalent. It treats that asymmetry as decisive even though no disclaimer existed in this case, reasoning that the statutory recognition of disclaimers is "tantamount to a statutory acknowledgement that ODP concerns can arise when PTA results in a later-expiring claim that is patentably indistinct." (P. 21.)

1. [ESTABLISHED] Double patenting and terminal disclaimers are "two sides of the same coin" (P. 20.), quoting the Board.

1. [ESTABLISHED, the doctrine's stated purpose] "A crucial purpose of ODP is to prevent an inventor from securing a second, later-expiring patent for non-distinct claims". (P. 16.)

1. [ESTABLISHED, good faith does not help] "An applicant's ability to show that it did not engage in gamesmanship in obtaining a grant of PTA is not sufficient to overcome a finding that it has received an unjust timewise extension of term." (P. 23.) And "there is no basis for an examiner to inquire into the intent of an applicant, or credit it". (P. 23.)

1. [ESTABLISHED, promises are not a defense] On the split-ownership risk, Cellect's undertaking never to divide its patents did not matter: "Promises do not substitute for sound applications of rules of law." (P. 23.) A terminal disclaimer would have been required to ensure common ownership "even in the absence of separate ownership". (P. 22.)

1. [ESTABLISHED, the timing rule practitioners must act on] "A terminal disclaimer is not an escape hatch to be deployed after a patent expires." (P. 25.) The court notes "Cellect had the opportunity to file terminal disclaimers during prosecution, even in the absence of an ODP rejection, yet it declined to do so". (P. 25.)

1. [ESTABLISHED, no partial remedy] Invalidating only the adjustment period was forfeited and, in any event, "invalidating only the adjustment would be tantamount to issuing a retroactive terminal disclaimer". (P. 24.) The consequence is that the whole claim falls, not just the adjusted tail.

1. [ESTABLISHED, and this is the limit of the holding] Only the asserted claims were invalidated. "the non-asserted claims in the challenged patents are entitled to their full term, including the duly granted PTA", unless separately found to be later-filed obvious variations of earlier-filed commonly owned claims. (P. 22.) The court says it has "no basis for consideration of that issue here." (P. 22.)

1. [ESTABLISHED, the reexamination gateway] A substantial new question of patentability existed. An examiner's awareness of the relatives, and willingness to issue such rejections in other applications of the same owner, does not show the question was considered here; the court adds that the absence of required disclaimers "itself strongly suggests that the examiner did not consider the issue." (P. 25.)

1. [IMPLEMENTED, the standard of review shapes the outcome] Double patenting is reviewed de novo as a question of law, while the substantial-new-question finding is reviewed only for substantial evidence. (P. 9.) The second standard is why the reexamination challenge failed on the record rather than on the law.

1. [ASSUMED, drafter's inference, flagged as such] Read with claim 15, the practical exposure of an adjusted continuation is claim-by-claim rather than patent-wide, so a family audit that asks only "which patents have adjustment" is the wrong unit. The opinion does not say this; it follows from the court limiting its holding to the asserted claims and expressly declining the rest.

Quotations, verified against the source

All from the Federal Circuit's opinion. Page locators computed from the docket stamp.

• "we agree with the USPTO that PTA and PTE should be treated differently from each other when determining whether or not claims are unpatentable under ODP" (P. 15.)
• "PTA is the expiration date after the PTA has been added" (P. 16.)
• "an unjustified attempt to force disparate statutes into one" (P. 16.)
• "A crucial purpose of ODP is to prevent an inventor from securing a second, later-expiring patent for non-distinct claims" (P. 16.)
• "each has its own independent framework established through an independent statutory schema" (P. 18.)
• "two sides of the same coin" (P. 20.)
• "regardless whether or not a terminal disclaimer is required or has been filed, must be based on the expiration date of the patent after PTA has been added" (P. 21.)
• "the non-asserted claims in the challenged patents are entitled to their full term, including the duly granted PTA" (P. 22.)
• "Promises do not substitute for sound applications of rules of law" (P. 23.)
• "there is no basis for an examiner to inquire into the intent of an applicant, or credit it" (P. 23.)
• "invalidating only the adjustment would be tantamount to issuing a retroactive terminal disclaimer" (P. 24.)
• "A terminal disclaimer is not an escape hatch to be deployed after a patent expires" (P. 25.)
• "the decision of the Board is affirmed" (P. 25.)

Tensions and open questions

The statutory asymmetry does the work, and it is thin. The court's textual argument is that Section 154 mentions terminal disclaimers and Section 156 does not. That is a real difference, but it is an inference from silence in the second statute, and the opinion leans on it while conceding no disclaimer was filed here at all.

How far does claim 15 reach? The court preserves non-asserted claims and then declines to consider them. Whether a later challenge to those claims would come out differently is left open by this opinion.

The reexamination gateway is doing quiet work. Claim 16 means an examiner's silence during prosecution is not a shield. Combined with claim 13, a patentee can be exposed years later to a rejection theory that was available, unraised, and no longer curable.

Unresolved by this record: how adjustment interacts with a family whose members do not share a priority date. Every patent here claimed priority from one application. Nothing in the passages read addresses the cross-family case.

What this record does and does not cover

The Background and all three numbered Discussion parts were read end to end. The parts most likely to be skipped, Part II on the equitable concerns and Part III on the substantial new question, were read in full and are in the ledger at claims 11 through 16, because they carry the timing rule and the good-faith holding that matter most to practice.

What was NOT read closely, and is therefore outside what this record can support: the statutory block quotations at pages 9 to 13 beyond their role in the court's reasoning; the underlying Board decisions and the joint appendix as separate documents, which this record knows only through the court's characterization; and the amicus briefs beyond the court's one-sentence acknowledgment of them. The figure on page 4 and the table on page 5 are images and were not recoverable from the text extraction, so any claim about the precise adjustment granted to each family member is outside this record.

Currency

This record was verified against its primary source on 2026-08-15. That is a fidelity check: the quotations, locators and attribution are accurate to that source. Whether the authority has since been narrowed, distinguished, abrogated or reversed has not been checked here. Confirm it still stands before relying on it.